~ Supply Chain Now Fully Secure for PF614-MPAR ~
~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~
~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~
~ Expects Early Interim Data in 1Q 2025 ~
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog